Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.

Date publication

mai 2023

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Panés J, Vermeire S, D'Haens GR, Danese S, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Gaya DR, Peyrin-Biroulet L, Dignass A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37139642

Résumé

STARDUST is a phase 3b randomized controlled trial comparing two ustekinumab treatment strategies in patients with Crohn's disease (CD): treat-to-target (T2T) versus standard of care (SoC).

Mots clés

Crohn's disease, health-related quality of life, standard of care, tight monitoring, treat-to-target, ustekinumab

Référence

United European Gastroenterol J. 2023 05 4;: